TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 21.6% in three months.  Over the past few quarters, Teva has successfully launched several biosimilars and other high-value, complex generics, with many more in the pipeline.  The company’s newer branded drugs, such as Austedo, Uzedy and Ajovy, are experiencing strong sales growth. ...